“Progress in HIV-1 Vaccine Development”, in 2nd National Conference on Human Retroviruses and Related Infections, Washington DC, 1995.,
“Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type1 envelope with a combination vaccine regimen”, J Infec Dis, vol. 177, pp. 301-9, 1998.,
“Immunization With Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, But Causes Sterile Abscesses and Unacceptable Reactogenicity”, PLoS One, vol. 5, no. 8, p. e11995, 2010.,
“A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults”, PLoS One, vol. 7, p. e41936, 2012.,
“A Phase II Study of Two HIV-1 Envelope Vaccines Comparing their Immunogenicity in Populations at Risk for Acquiring HIV-1 Infection”, AIDS Res HumRetroviruses, vol. 16, pp. 907-19, 2000.,
“Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers”, J Infec Dis, vol. 183, pp. 1343-52, 2001.